BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

13288 related articles for article (PubMed ID: 10808371)

  • 1. Histamine: a novel approach to cancer immunotherapy.
    Hellstrand K; Brune M; Naredi P; Mellqvist UH; Hansson M; Gehlsen KR; Hermodsson S
    Cancer Invest; 2000; 18(4):347-55. PubMed ID: 10808371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histamine and cytokine therapy.
    Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
    Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine in cancer immunotherapy: a preclinical background.
    Hellstrand K
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):35-40. PubMed ID: 12068387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
    Hellstrand K; Brune M; Dahlgren C; Hansson M; Hermodsson S; Lindnér P; Mellqvist UH; Naredi P
    Med Oncol; 2000 Nov; 17(4):258-69. PubMed ID: 11114704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites.
    Brune M; Hansson M; Mellqvist UH; Hermodsson S; Hellstrand K
    Eur J Haematol; 1996 Oct; 57(4):312-9. PubMed ID: 8982295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
    Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
    Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histamine in cancer immunotherapy.
    Hellstrand K; Hermodsson S; Brune M; Naredi P; Carneskog J; Mellqvist UH
    Scand J Clin Lab Invest; 1997 May; 57(3):193-202. PubMed ID: 9238754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.
    Agarwala SS; Sabbagh MH
    Expert Opin Biol Ther; 2001 Sep; 1(5):869-79. PubMed ID: 11728221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant histamine in cancer immunotherapy.
    Hellstrand K; Hansson M; Hermodsson S
    Semin Cancer Biol; 2000 Feb; 10(1):29-39. PubMed ID: 10888269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histamine as an adjunct to immunotherapy.
    Naredi P
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine and interleukin-2 in acute myelogenous leukemia.
    Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
    Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
    Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
    Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine protects T cells and natural killer cells against oxidative stress.
    Hansson M; Hermodsson S; Brune M; Mellqvist UH; Naredi P; Betten A; Gehlsen KR; Hellstrand K
    J Interferon Cytokine Res; 1999 Oct; 19(10):1135-44. PubMed ID: 10547153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
    Brune M; Hellstrand K
    Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histaminergic regulation of interferon-gamma (IFN-gamma) production by human natural killer (NK) cells.
    Asea A; Hansson M; Czerkinsky C; Houze T; Hermodsson S; Strannegård O; Hellstrand K
    Clin Exp Immunol; 1996 Aug; 105(2):376-82. PubMed ID: 8706348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2.
    Hellstrand K; Hermodsson S
    Int Arch Allergy Appl Immunol; 1990; 92(4):379-89. PubMed ID: 2150668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of reactive oxygen metabolites in the transcriptional regulation of IFN-gamma gene expression by histamine in NK cells following IL-2 stimulation.
    Houze TA; Larsson PA; Hellstrand K; Gustavsson B
    Cell Biol Int; 1996 Sep; 20(9):589-98. PubMed ID: 8948120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
    Perz JB; Ho AD
    Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells.
    Kozar K; Kaminski R; Giermasz A; Basak G; Zagozdzon R; Rybczynska J; Wasik M; Lasek W; Jakobisiak M; Golab J
    Oncol Rep; 2002; 9(2):427-31. PubMed ID: 11836621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.
    Sim GC; Wu S; Jin L; Hwu P; Radvanyi LG
    Oncotarget; 2016 Jun; 7(24):36074-36091. PubMed ID: 27153543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 665.